Rosutin EZ Tablet 20 mg + 10 mg is a powerful combination therapy designed to provide enhanced lipid-lowering effects in patients with hypercholesterolemia and mixed dyslipidemia. This tablet combines Rosuvastatin 20 mg, a potent HMG-CoA reductase inhibitor, with Ezetimibe 10 mg, a cholesterol absorption inhibitor, targeting cholesterol reduction through dual mechanisms. This formulation is particularly useful for patients who cannot achieve LDL-C goals with statin monotherapy or require more intensive therapy for cardiovascular risk reduction.

Rosutin EZ 20/10 mg is indicated in heterozygous and homozygous hypercholesterolemia, mixed dyslipidemia (Fredrickson Type IIa and IIb), and as primary prevention of cardiovascular disease in high-risk patients. By lowering LDL cholesterol, total cholesterol, and triglycerides while modestly increasing HDL cholesterol, it effectively improves the overall lipid profile and reduces the risk of atherosclerosis and related cardiovascular events.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Rosutin EZ Tablet 20 mg + 10 mg is recommended for:

• Heterozygous Hypercholesterolemia (Familial and Non-familial)

• Mixed Dyslipidemia (Fredrickson Type IIa and IIb)

• Primary prevention of cardiovascular disease in high-risk patients

• Patients not achieving LDL-C targets with statin monotherapy

Therapeutic Class

Combination Therapy: Statin + Cholesterol Absorption Inhibitor

Pharmacology

• Rosuvastatin 20 mg selectively inhibits HMG-CoA reductase, the key enzyme in cholesterol biosynthesis. This decreases hepatic cholesterol production, upregulates LDL receptors, and enhances LDL clearance from the bloodstream.

• Ezetimibe 10 mg inhibits the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestine, reducing the absorption of dietary and biliary cholesterol.

• Combined action: Dual inhibition of cholesterol synthesis and absorption provides greater LDL-C reduction than either agent alone, making it suitable for patients with elevated cholesterol levels resistant to monotherapy.

Dosage and Administration

• Adults: One tablet once daily, orally

• Can be taken with or without food, at any convenient time of the day

• Dose adjustments may be required for renal impairment or based on patient response

• Regular lipid monitoring is recommended to assess treatment efficacy

Special Populations:

• Pediatric patients: Safety and efficacy not established

• Elderly patients: Monitor for muscle or liver-related effects

Drug Interactions

• Cyclosporine: Increases Rosuvastatin exposure; limit use

• Gemfibrozil: May increase myopathy risk; avoid combination

• Warfarin: Monitor INR closely

• Other lipid-lowering drugs (fibrates, niacin): Increased risk of muscle-related side effects

• Ezetimibe: Minimal interactions, but combined therapy requires monitoring of liver enzymes and muscle symptoms

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Contraindications

• Hypersensitivity to Rosuvastatin, Ezetimibe, or any component

• Active liver disease or unexplained persistent elevations in hepatic enzymes

• Pregnancy and lactation

• Pediatric patients under recommended age

Side Effects

• Common: Headache, myalgia, fatigue, abdominal pain, constipation, nausea

• Rare: Muscle toxicity (myopathy, rhabdomyolysis) or liver enzyme elevations

• Patients should report unexplained muscle pain, tenderness, or weakness immediately

Pregnancy and Lactation

• Not recommended during pregnancy or breastfeeding

• Use only if clearly necessary and under medical supervision

Precautions and Warnings

• Liver monitoring: Check hepatic transaminases before initiating therapy and periodically during treatment

• Muscle-related effects: Risk increases in elderly patients, high-dose therapy, renal impairment, or when combined with interacting medications

• Renal impairment: Dose adjustment may be necessary

Storage Conditions

Store below 30°C, protected from light and moisture. Keep out of reach of children.

Mode of Action

• Rosuvastatin: Inhibits cholesterol synthesis in the liver and increases LDL clearance

• Ezetimibe: Reduces intestinal absorption of cholesterol

• Combined effect: Significant reduction in LDL-C, total cholesterol, and triglycerides, with modest HDL improvement, supporting cardiovascular health.